Related Experiment Video
Updated: Jan 7, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for
Prajakta Patil1, Mrunal Desai1, Gayathri Baburaj2
1Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Background:
As lung cancer treatment has progressed, there has been an increase in awareness of the short- and long-term adverse effects of targeted cancer therapies of tyrosine kinase inhibitors, particularly cardiovascular toxicities.
Methods:
The current study assessed the potential drug-drug interactions using interaction checkers (IBM Micromedex and Drugs.com). Molecular docking was employed to further investigate the involvement of human ether-à-go-go-related gene (hERG) and pregnane X receptor (PXR) proteins to elucidate their potential interactions and their underlying mechanisms.
Results:
A total of 74 pharmacokinetic and 105 pharmacodynamic interactions were detected between tyrosine kinase inhibitors and cardiovascular drugs, along with a report on the severity and level of documentation. A considerable fraction of molecular modelling outcomes concurred with information from drug-drug interaction checkers. The binding energies of tyrosine kinase inhibitors with hERG and PXR were high, indicating significant interactions. The cardiovascular drug class encompasses calcium channel blockers, antiarrhythmic medicines, and statins, which were observed to exhibit synergistic interactions. The identification of these potential drug-drug interactions involving CYP3A4, P-gp, and hERG proteins can be utilized in therapy optimization in clinical settings.
Conclusion:
This study will aid clinicians in designing safe dosage regimens for patients with lung cancer. In cases where patients have multiple comorbidities, it is essential to study the clinical aspects to design efficient chemotherapy and manage adverse effects and toxicities.
Insights
This study identified numerous drug-drug interactions between tyrosine kinase inhibitors and cardiovascular drugs, highlighting risks for lung cancer patients. Understanding these interactions, particularly with hERG and PXR proteins, is crucial for safe treatment regimens.
Area of Science:
- Pharmacology
- Oncology
- Cardiology
Background:
- Targeted cancer therapies, like tyrosine kinase inhibitors (TKIs), are increasingly used for lung cancer.
- Awareness of cardiovascular toxicities associated with TKIs is growing.
- Managing adverse effects is critical for effective lung cancer treatment.
Purpose of the Study:
- To assess potential drug-drug interactions (DDIs) between TKIs and cardiovascular drugs.
- To investigate the molecular mechanisms of these DDIs involving hERG and PXR proteins.
- To provide data for optimizing lung cancer patient treatment regimens.
Main Methods:
- Utilized interaction checkers (IBM Micromedex, Drugs.com) to identify DDIs.
- Employed molecular docking to study interactions with hERG and PXR proteins.
- Analyzed pharmacokinetic and pharmacodynamic interactions.
Main Results:
- Detected 74 pharmacokinetic and 105 pharmacodynamic interactions between TKIs and cardiovascular drugs.
- Molecular modeling results largely agreed with interaction checker findings.
- High binding energies observed between TKIs and hERG/PXR proteins, indicating significant interactions.
- Synergistic interactions noted with calcium channel blockers, antiarrhythmics, and statins.
Conclusions:
- Identified potential DDIs involving CYP3A4, P-gp, and hERG proteins.
- Findings can aid clinicians in designing safe dosage regimens for lung cancer patients.
- Clinical management of comorbidities and toxicities is essential for efficient chemotherapy.
More Related Videos
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...